Teva Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Pharma (TEVA) Tops Q4 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance
February 10, 2021 7:03 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.68, $0.05 better than the analyst estimate of $0.63. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.37 billion.
GUIDANCE:
Teva Pharma sees FY2021 EPS of $2.50-$2.70, versus the consensus of $2.63. Teva Pharma sees FY2021 revenue of $16.4-16.8 billion, versus the consensus of $16.76 billion.
2021 business outlook:
Revenues are expected to be $16.4 - $16.8 billion (2020 actual results... More